Eli Lilly and Company

LLY | $750.77 -0.12% -0.23% 1.8M

(0.0% 1d) (-1.6% 1m) (101.6% 1y) (0.0% 2d) (0.0% 3d) (-0.1% 7d) (-5.47% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 713,354,965,628
http://www.lilly.com
Sec Filling | Patents | 33625 employees

(US) Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Drugs

Alimta (Pemetrexed disodium)
Amyvid (Florbetapir F 18)
Bamlanivimab (Bamlanivimab)
Baqsimi (glucagon)
BASAGLAR KwikPen (Insulin glargine)
BASAGLAR Tempo Pen (Insulin glargine)
Cialis (Tadalafil)
Cymbalta (Duloxetine hydrochloride)
CYRAMZA (ramucirumab)
Effient (Prasugrel hydrochloride)
EMGALITY (galcanezumab-gnlm)
Etesevimab (Etesevimab)
Evista (Raloxifene hydrochloride)
Forteo (Teriparatide)
Gemzar (Gemcitabine hydrochloride)
Glucagon (glucagon)
Humalog (Insulin lispro)
Humalog Junior KwikPen (Insulin lispro)
Humalog KwikPen (Insulin lispro)
Humalog Mix50/50 (Insulin lispro)
Humalog Mix50/50 KwikPen (Insulin lispro)
Humalog Mix75/25 (Insulin lispro)
Humalog Mix75/25 KwikPen (Insulin lispro)
Humalog Tempo Pen (Insulin lispro)
HUMATROPE (Somatropin)
Humulin 70/30 (Insulin human)
Humulin 70/30 KwikPen (Insulin human)
Humulin N (Insulin human)
Humulin R (Insulin human)
Humulin R U-500 (Insulin human)
Humulin R U-500 KwikPen (Insulin human)
Insulin Lispro (Insulin lispro)
Insulin Lispro Junior KwikPen (Insulin lispro)
Insulin Lispro KwikPen (Insulin lispro)
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (Insulin lispro)
LARTRUVO (olaratumab)
LYUMJEV (Insulin lispro-aabc)
LYUMJEV Junior KwikPen (Insulin lispro-aabc)
LYUMJEV KwikPen (Insulin lispro-aabc)
LYUMJEV Tempo Pen (Insulin lispro-aabc)
Olumiant (baricitinib)
Portrazza (necitumumab)
RETEVMO (selpercatinib)
Reyvow (lasmiditan)
Sterile Diluent (diluent)
Strattera (Atomoxetine hydrochloride)
Symbyax (Olanzapine and Fluoxetine hydrochloride)
TALTZ (ixekizumab)
TAUVID (Flortaucipir F-18)
Trulicity (Dulaglutide)
Verzenio (abemaciclib)
Zyprexa (Olanzapine)
ZYPREXA Intramuscular (Olanzapine)
ZYPREXA Relprevv (Olanzapine pamoate)
ZYPREXA Zydis (Olanzapine)

add to watch list Paper trade email alert is off

OncoCyte Corporation

OCX | $2.53 -6.64% -6.9% 110K

Health Technology

(0.0% 1d) (-16.2% 1m) (721.2% 1y) (0.0% 2d) (0.0% 3d) (-13.0% 7d) (-94.92% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 20,899,728
http://www.oncocyte.com
Sec Filling | Patents | 33 employees

(US) OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.

cancer diagnostics

add to watch list Paper trade email alert is off

Anavex Life Sciences Corp.

AVXL | $4.23 -1.51% -1.54% 1.1M

Health Technology

(0.0% 1d) (-12.2% 1m) (-48.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 347,335,922
http://www.anavex.com
Sec Filling | Patents | 16 employees

(US) Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

neurodegenerative alzheimer nervous system parkinson treatment alzheimer’s

add to watch list Paper trade email alert is off